Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

International Journal of Cancer

Volumn 92, Issue 4, 2001, Pages 583-588

  Damia, Giovanna ^a   Silvestri, Simonetta ^b   Carrassa, Laura ^c   Filiberti, Laura ^a   Faircloth, Glynn T ^a   Liberi, Giordano ^d   Foiani, Marco ^a   D'Incalci, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PharmaMar USA Inc   (United States)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

ATM; DNA repair; DNA protein kinase; ET 743; Marine compound; Nucleotide excision repair

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; TRABECTEDIN; WORTMANNIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL CULTURE; COLON CARCINOMA; CYTOTOXICITY; DNA REPAIR; DRUG BINDING; DRUG DNA INTERACTION; EXCISION REPAIR; GENE DELETION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CAMPTOTHECIN; CELL SURVIVAL; CHO CELLS; CRICETINAE; DIOXOLES; DNA; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0035874074     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1221     Document Type: Article

References (30)

1. In vitro anti-tumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
2. Progress in the acquisition of new marine-derived anti-cancer compounds: Development of ecteinascidin-743 (ET-743)
3. Ecteinascidin-743, a new marine natural product with potent anti-tumor activity on human ovarian carcinoma xenografts
4. Final results of a phase I study of ecteinascidin-743 (ET-743) 24 hours (h) continous infusion (CI) in advanced solid tumors (AST) patients (pts)
5. A phase I and pharmacokinetic trial of ecteinascidin-743 (ET-743) administered as a 72 hours continuous infusion
6. NMR-based model of an ecteinascidin 743-DNA adduct
7. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent anti-tumor compound from the Caribbean tunicate Ecteinascidia turbinata
8. Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level
9. Ecteinascidin-743 (ET-743), a natural marine compound, with unique mechanism of action
10. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anti-cancer drug that selectively alkylates DNA in the minor groove
11. Recent progress with the DNA repair mutants of Chinese hamster ovary cells
12. Cisplatinum and Taxol induce different patterns of p53 phosphorylation
13. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents
14. The role of DNA mismatch repair in drug resistance
15. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
16. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin
17. Differential recognition of minor groove Et 743-DNA adducts by UvrABC nuclease
18. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
19. Interference of transcriptional activation by the anti-neoplastic drug ET-743
20. Mammalian mutants defective in the response to ionizing radiation-induced DNA damage
21. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin
22. The DNA-dependent protein kinase
23. Splitting the ATM: Distinct repair and checkpoint defects in ataxia-telangiectasia
24. p53 and ATM: Cell cycle, cell death, and cancer
25. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53
26. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
27. Sister chromatid exchanges and DNA topoisomerase II inhibitors: Effect of low concentrations of etoposide (VP-16) in ataxia telangiectasia lymphoblastoid cell lines
28. Chromosomal breakage correlates with delayed lethality in normal and ataxia telangiectasia cell lines treated with bleomycin
29. Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells